The FDA has approved the first gene therapy designed to treat deafness caused by a specific genetic mutation. This groundbreaking treatment targets the OTOF gene, which is crucial for transmitting sound signals from the inner ear to the brain. In clinical trials involving 20 participants, 80% experienced improved hearing sensitivity, and 42% achieved normal hearing within six months, with the therapy demonstrating safety and tolerability. AI
IMPACT This gene therapy breakthrough demonstrates the potential of advanced biological engineering, though it does not directly involve AI.
RANK_REASON FDA approval of a novel gene therapy for a medical condition. [lever_c_demoted from significant: ic=1 ai=0.1]
- Daniel Choo
- Eli Lilly
- Harvard Medical School
- Karolinska Institute
- OTOF gene
- Regeneron
- FDA
- University of Cincinnati College of Medicine
- Zheng-Yi Chen
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
